12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OMS721: Phase I data

A double-blind, placebo-controlled, European Phase I trial in healthy volunteers showed that single ascending-doses of subcutaneous OMS721 were well tolerated with no treatment-related adverse events reported and no clinically significant abnormalities...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >